|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Su CQ: Survivin in survival of
hepatocellular carcinoma. Cancer Lett. 379:184–190. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cherepanova OA, Gomez D, Shankman LS,
Swiatlowska P, Williams J, Sarmento OF, Alencar GF, Hess DL, Bevard
MH, Greene ES, et al: Activation of the pluripotency factor OCT4 in
smooth muscle cells is atheroprotective. Nat Med. 22:657–665. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu T, Liu S, Breiter DR, Wang F, Tang Y
and Sun S: Octamer 4 small interfering RNA results in cancer stem
cell-like cell apoptosis. Cancer Res. 68:6533–6540. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu
P, Chen KK, Lopez JP, Poon RT and Fan ST: Octamer 4 (Oct4) mediates
chemotherapeutic drug resistance in liver cancer cells through a
potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology.
52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Linn DE, Yang X, Sun F, Xie Y, Chen H,
Jiang R, Chen H, Chumsri S, Burger AM and Qiu Y: A role for OCT4 in
tumor initiation of drug-resistant prostate cancer cells. Genes
Cancer. 1:908–916. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ezeh UI, Turek PJ, Reijo RA and Clark AT:
Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are
expressed in both seminoma and breast carcinoma. Cancer.
104:2255–2265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gu G, Yuan J, Wills M and Kasper S:
Prostate cancer cells with stem cell characteristics reconstitute
the original human tumor in vivo. Cancer Res. 67:4807–4815. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YC, Hsu HS, Chen YW, Tsai TH, How CK,
Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, et al: Oct-4
expression maintained cancer stem-like properties in lung
cancer-derived CD133-positive cells. PLoS One. 3:e26372008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Atlasi Y, Mowla SJ, Ziaee SA and Bahrami
AR: OCT-4, an embryonic stem cell marker, is highly expressed in
bladder cancer. Int J Cancer. 120:1598–1602. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ,
Tsai TH, Chou SH, Chien CS, Ku HH and Lo JF: Positive correlations
of Oct-4 and Nanog in oral cancer stem-like cells and high-grade
oral squamous cell carcinoma. Clin Cancer Res. 14:4085–4095. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Z, Xu WR, Qian H, Zhu W, Bu XF, Wang
S, Yan YM, Mao F, Gu HB, Cao HL, et al: Oct4, a novel marker for
human gastric cancer. J Surg Oncol. 99:414–419. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou X, Huang GR and Hu P: Over-expression
of Oct4 in human esophageal squamous cell carcinoma. Mol Cells.
32:39–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang R, Jin S, Rao W, Song F, Yin Q, Wang
Y, Wang L, Xi Y, Zhang X, Wang M, et al: OVA12, a novel tumor
antigen, promotes cancer cell growth and inhibits
5-fluorouracil-induced apoptosis. Cancer Lett. 357:141–151. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Athanasoula KCh, Gogas H, Polonifi K,
Vaiopoulos AG, Polyzos A and Mantzourani M: Survivin beyond
physiology: Orchestration of multistep carcinogenesis and
therapeutic potentials. Cancer Lett. 347:175–182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salzano G, Riehle R, Navarro G, Perche F,
De Rosa G and Torchilin VP: Polymeric micelles containing
reversibly phospholipid-modified anti-survivin siRNA: A promising
strategy to overcome drug resistance in cancer. Cancer Lett.
343:224–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Li Z, Lin Z, Zhao B, Wang Y, Peng
R, Wang M, Lu C, Shi G and Shen Y: 17-DMCHAG, a new geldanamycin
derivative, inhibits prostate cancer cells through Hsp90 inhibition
and survivin downregulation. Cancer Lett. 362:83–96. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanda N, Seno H, Konda Y, Marusawa H,
Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y,
et al: STAT3 is constitutively activated and supports cell survival
in association with survivin expression in gastric cancer cells.
Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gritsko T, Williams A, Turkson J, Kaneko
S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al:
Persistent activation of stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Glienke W, Hausmann E and Bergmann L:
Downregulation of STAT3 signaling induces apoptosis but also
promotes anti-apoptotic gene expression in human pancreatic cancer
cell lines. Tumour Biol. 32:493–500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao C, Li H, Lin HJ, Yang S, Lin J and
Liang G: Feedback activation of STAT3 as a cancer drug-resistance
mechanism. Trends Pharmacol Sci. 37:47–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zeng R, Tang Y, Zhou H, Liu Y, Huang J, Li
L, Liu W, Feng Y, Zhou Y, Chen T, et al: STAT3 mediates multidrug
resistance of Burkitt lymphoma cells by promoting antioxidant
feedback. Biochem Biophys Res Commun. 488:182–188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang S, Chen M, Shen Y, Shen W, Guo H,
Gao Q and Zou X: Inhibition of activated Stat3 reverses drug
resistance to chemotherapeutic agents in gastric cancer cells.
Cancer Lett. 315:198–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagaraj NS, Washington MK and Merchant NB:
Combined blockade of Src kinase and epidermal growth factor
receptor with gemcitabine overcomes STAT3-mediated resistance of
inhibition of pancreatic tumor growth. Clin Cancer Res. 17:483–493.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo Y, Mantel C, Hromas RA and Broxmeyer
HE: Oct-4 is critical for survival/antiapoptosis of murine
embryonic stem cells subjected to stress: effects associated with
Stat3/survivin. Stem Cells. 26:30–34. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Friedrichs K, Gluba S, Eidtmann H and
Jonat W: Overexpression of p53 and prognosis in breast cancer.
Cancer. 72:3641–3647. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Umeda S, Kanda M and Kodera Y: Emerging
evidence of molecular biomarkers in hepatocellular carcinoma.
Histol Histopathol. 33:343–355. 2018.PubMed/NCBI
|
|
29
|
Yuan F, Zhou W, Zou C, Zhang Z, Hu H, Dai
Z and Zhang Y: Expression of Oct4 in HCC and modulation to
wnt/β-catenin and TGF-β signal pathways. Mol Cell Biochem.
343:155–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee TI, Jenner RG, Boyer LA, Guenther MG,
Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K,
et al: Control of developmental regulators by Polycomb in human
embryonic stem cells. Cell. 125:301–313. 2006. View Article : Google Scholar : PubMed/NCBI
|
